Journal of Neurology

, Volume 253, Supplement 5, pp v25–v32 | Cite as

Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects




Although IVIg is highly effective in several autoimmune neuromuscular disorders (neuropathies, myopathies and neuromuscular junction disorders), its effectiveness in autoimmune or neuroinflammatory CNS diseases, with the exception of multiple sclerosis, has not been explored. Emerging data suggest that IVIg may have a role not only in certain antibody-mediated CNS diseases but also in some neurodegenerative disorders associated with “neuroinflammation” mediated by proinflammatory cytokines.


Data from a previously reported controlled study conducted in patients with stiff person syndrome (SPS) are presented as a paradigm of a CNS disorder associated with specific autoantibodies responding to IVIg. Emerging data using IVIg in various neuroinflammatory and neurodegenerative conditions such as Alzheimers disease, postpolio syndrome (PPS), fibrotic disorders, chronic painful conditions and narcoplepsy are summarized.


On the basis of a double-blind placebo-controlled trial conducted in SPS patients with high anti-GAD antibodies, IVIg was shown to be effective resulting in improvement of stiffness and heightened sensitivity scores and increasing the patients’ ability to carry out daily activities. In SPS, IVIg also suppressed the anti-GAD antibodies titers probably via an anti-idiotypic effect. A controlled study in patients with PPS, showed reduction in cytokines in serum and CSF with concomitant improvement in the patients’ strength and ability to carry out their daily activities. The effect of IVIg in a small number of patients with Alzheimer’s disease was promising by reducing the ADAS-cog scores, suggesting a reversal of disease progression. IVIg has been shown to have an effect on tissue fibrosis and in certain subacute painful conditions by suppressing cytokines that mediate fibrosis or pain. In another uncontrolled study, IVIg reduced the number of cataplectic attacks in narcolepsy patients.


IVIg is effective in anti-GAD-positive patients with SPS. Whether it is also effective in other GAD-positive CNS disorders such as epilepsies, cerebellar degenerations or Batten’s disease need to be studied in control trials. Emerging data suggest that IVIg, by suppressing proinflammatory cytokines, may exert a beneficial effect in patients with Alzheimer’s disease, postpolio syndrome, chronic pain syndromes, fibrotic disorders and narcolepsy. Controlled studies are being planned or conducted to substantiate the benefit of IVIg in neurodegenerative disorders.

Key words

autoimmune disorders IVIg neuroinflammation neurodegeneration 


  1. 1.
    Akiyama H, Barger S, Barnum S et al. (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421PubMedCrossRefGoogle Scholar
  2. 2.
    Amato AA, Cornman EW, Kissel JT (1994) Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 44:1652–1654PubMedGoogle Scholar
  3. 3.
    Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99–104PubMedCrossRefGoogle Scholar
  4. 4.
    Askanas V, Dalakas MC, Engel WK (2006) Inclusion-body myositis: clinical and pathologic aspects, and basic research potentially relevant to treatment. Neurology 24(Suppl 1):66Google Scholar
  5. 5.
    Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689–1690PubMedCrossRefGoogle Scholar
  6. 6.
    Barker RAMC (1997) Successful treatment of stiff-man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 62:426PubMedCrossRefGoogle Scholar
  7. 7.
    Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993–2000PubMedCrossRefGoogle Scholar
  8. 8.
    Dalakas MC (1995) Pathogenetic mechanisms of postpolio syndrome: Morphological, electrophysiological, virological and immunopathological correlations. Ann NY Acad Sci 753:167–185PubMedGoogle Scholar
  9. 9.
    Dalakas MC (1998) Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 55:1509–1512PubMedCrossRefGoogle Scholar
  10. 10.
    Dalakas MC (1999) Autoantibodies and immunopathogenesis of the stiff-person syndrome. In: Levy LM (moderator) The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 131:522–530PubMedGoogle Scholar
  11. 11.
    Dalakas MC (1999) Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opinion in Neurology 12:403–409CrossRefGoogle Scholar
  12. 12.
    Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531–1535PubMedGoogle Scholar
  13. 13.
    Dalakas MC, Li M, Fujii M, Jacobowitz DM (2001) Stiff-person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 57:780–785PubMedGoogle Scholar
  14. 14.
    Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immunoglobulin for stiffperson syndrome. N Engl J of Med 345:1870–1876CrossRefGoogle Scholar
  15. 15.
    Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323–327PubMedGoogle Scholar
  16. 16.
    Dalakas MC (2002) Proinflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome? J Neurol Sci 205:5–8PubMedCrossRefGoogle Scholar
  17. 17.
    Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982PubMedCrossRefGoogle Scholar
  18. 18.
    Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neurological disorders: evidence-based indications and safety profile. Pharmacol Therapeutics 102:177–193CrossRefGoogle Scholar
  19. 19.
    Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2375PubMedCrossRefGoogle Scholar
  20. 20.
    Dalakas MC (2004) Inhibiting leucocyte recruitment to the brain by IVIg. Is it relevant to the treatment of demyelinating CNS disorders? (Editorial) Brain 127:2569–2571PubMedCrossRefGoogle Scholar
  21. 21.
    Dalakas MC (2005) The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 252(S):19–25CrossRefGoogle Scholar
  22. 22.
    Dalakas MC (2006) Inflammatory, immune and viral aspects of inclusion body myositis. Neurology 66(Suppl):533–538Google Scholar
  23. 23.
    Dalakas MC (2006) Signaling pathways and immunobiology of inflammatory myopathies. Nature Clinic Practice 2:219–227CrossRefGoogle Scholar
  24. 24.
    Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905–908PubMedCrossRefGoogle Scholar
  25. 25.
    Daw K, Ujihara N, Atkinson M, Powers AC (1996) Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156:818–825PubMedGoogle Scholar
  26. 26.
    Dinkel K MH, Jury KM et al. (1998) Inhibition of gama-aminoutric acid synthesis by glutamic acid decarboxylase autoantibodies in Stiff-Man syndrome. Ann Neurol 44:194–201PubMedCrossRefGoogle Scholar
  27. 27.
    Dodel R, Hampel H, Depboylu C et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol 52:253–256PubMedCrossRefGoogle Scholar
  28. 28.
    Dodel RC, Du Y, Depboylu C et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:1472–1474PubMedCrossRefGoogle Scholar
  29. 29.
    Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M (2003) Human anti-beta-amyloid antibodies block betaamyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126:1935–1939PubMedCrossRefGoogle Scholar
  30. 30.
    Ellis MT, Atkinson AM (1996) The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nature Medicine 2:148–153PubMedCrossRefGoogle Scholar
  31. 31.
    Goebel A, Netal S, Schedel R, Sprotte G (2002) Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 3:119–127PubMedCrossRefGoogle Scholar
  32. 32.
    Goebel A Goebel A, Vogel H et al. (2005) Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol 162:184–189PubMedCrossRefGoogle Scholar
  33. 33.
    Goebel A, Stock M, Deacon R, Sprotte G,Vincent A (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463–464PubMedCrossRefGoogle Scholar
  34. 34.
    Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T (2002) Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 5:9–13CrossRefGoogle Scholar
  35. 35.
    Gonzalez H, Khademi M, Andersson M et al. (2004) Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150:139–144PubMedCrossRefGoogle Scholar
  36. 36.
    Gonzales H et al. (2006) Intravenous immunoglobulin for the post-polio syndrome; a randomized controlled trial. Lancet Neurology 5:493–500CrossRefGoogle Scholar
  37. 37.
    Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C et al. (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58:225–230PubMedCrossRefGoogle Scholar
  38. 38.
    Huizing M, Rakocevic G, Sparks SE, Mamali I, Goldfarb L, Krasnewich D, Gahl WA, Dalakas MC (2004) Hypoglycosylation of a-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metabolism 81:196–202CrossRefGoogle Scholar
  39. 39.
    Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P (2004) IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127:2649–2656PubMedCrossRefGoogle Scholar
  40. 40.
    Levy LM, Levy-Reis I, Fujii M, Dalakas MC (2005) Brain g-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62:970–974PubMedCrossRefGoogle Scholar
  41. 41.
    Meinck HM, Ricker K, Hulser PJ, Solimena M (1995) Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 242:134–142PubMedCrossRefGoogle Scholar
  42. 42.
    Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P et al. (2004) Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 63:2146–2148PubMedGoogle Scholar
  43. 43.
    Pearce DA, Atkinson M, Tagle DA (2004) Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 63:2001–2005PubMedGoogle Scholar
  44. 44.
    Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K et al. (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55:46–50PubMedGoogle Scholar
  45. 45.
    Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC, Ortqvist E, Hampe CS (2005) Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 75:7755–7762Google Scholar
  46. 46.
    Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes. Brain 128:1887–1896PubMedCrossRefGoogle Scholar
  47. 47.
    Rakocevic G, Raju R, Semino-Mora, Dalakas MC (2006) Stiff Person Syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (In press)Google Scholar
  48. 48.
    Schmidt J, Voss JG, Raju R, Dalakas MC (2004) Effect of immunotherapy on expression of cytokines and chemokines in relation to beta-amyloid and ubiquitin in the muscle of patients with sporadic inclusion body myositis. Ann Neurol 56:63Google Scholar
  49. 49.
    Schmidt J et al. (2005) Distinct interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Neurology 64(Suppl 1):A331–A332Google Scholar
  50. 50.
    Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Int Med 121:259–262PubMedGoogle Scholar
  51. 51.
    Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555–1560PubMedCrossRefGoogle Scholar
  52. 52.
    Vasconcelos OM, Raju R, Dalakas MC (2002) GNE mutations in an American family with quadriceps-sparing IBM. Neurology 59:1776–1780PubMedGoogle Scholar
  53. 53.
    Vasconcelos OM, Dalakas MC (2003) Therapies for stiff person syndrome. Current Treatment Options in Neurology 5:79–90PubMedGoogle Scholar
  54. 54.
    Vernino S, Lennon VA (2004) Autoantibody profiles and neurological correlations of Thymoma. Clin Cancer Res 10:7270–7275PubMedCrossRefGoogle Scholar
  55. 55.
    Weinberger DR (2001) Anxiety at the frontier of molecular medicine. N Engl J Med 344:1247–1249PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  1. 1.Neuromuscular Diseases SectionNINDS National Institutes of Health, Building 10, Room 4N248Bethesda, MD 20892-1382USA

Personalised recommendations